NYSE:MRK - Merck & Co., Inc. Stock Price, News, & Analysis

Merck & Co., Inc. trades on the New York Stock Exchange (NYSE) under the ticker symbol "MRK."

Merck & Co., Inc. announced a quarterly dividend on Tuesday, July 24th. Shareholders of record on Monday, September 17th will be given a dividend of $0.48 per share on Friday, October 5th. This represents a $1.92 annualized dividend and a yield of 2.78%. The ex-dividend date of this dividend is Friday, September 14th. View Merck & Co., Inc.'s Dividend History.

Merck & Co., Inc. declared that its Board of Directors has initiated a stock buyback plan on Saturday, December 2nd 2017, which permits the company to buyback $10,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization permits the company to reacquire shares of its stock through open market purchases. Stock buyback plans are usually an indication that the company's leadership believes its stock is undervalued.

Merck & Co., Inc. (NYSE:MRK) issued its quarterly earnings results on Friday, July, 27th. The company reported $1.06 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $1.03 by $0.03. The business earned $10.47 billion during the quarter, compared to the consensus estimate of $10.28 billion. Merck & Co., Inc. had a return on equity of 32.68% and a net margin of 3.67%. Merck & Co., Inc.'s quarterly revenue was up 5.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.01 earnings per share. View Merck & Co., Inc.'s Earnings History.

Merck & Co., Inc. is scheduled to release their next quarterly earnings announcement on Friday, October, 26th 2018. View Earnings Estimates for Merck & Co., Inc..

Merck & Co., Inc. issued an update on its FY18 earnings guidance on Friday, July, 27th. The company provided EPS guidance of $4.22-4.30 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.24. The company issued revenue guidance of $42-42.8 billion, compared to the consensus revenue estimate of $42.12 billion.

17 brokerages have issued 12-month price objectives for Merck & Co., Inc.'s stock. Their predictions range from $58.83 to $77.00. On average, they anticipate Merck & Co., Inc.'s share price to reach $66.3887 in the next year. This suggests that the stock has a possible downside of 3.9%. View Analyst Price Targets for Merck & Co., Inc..

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merck & Co., Inc. in the last year. There are currently 4 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Merck & Co., Inc..

Some companies that are related to Merck & Co., Inc. include Johnson & Johnson (JNJ), Pfizer (PFE), Novartis (NVS), AbbVie (ABBV), Novo Nordisk A/S (NVO), Abbott Laboratories (ABT), Eli Lilly And Co (LLY), Sanofi (SNY), AstraZeneca (AZN), GlaxoSmithKline (GSK), Bristol-Myers Squibb (BMY), Bayer (BAYRY), Celgene (CELG), Allergan (AGN) and Shire (SHPG).

Press coverage about MRK stock has been trending somewhat positive this week, according to Accern Sentiment Analysis. The research firm identifies negative and positive press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Merck & Co., Inc. earned a news and rumor sentiment score of 0.11 on Accern's scale. They also gave media coverage about the company an impact score of 46.87 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near future. View Recent Headlines for Merck & Co., Inc..

Merck & Co., Inc.'s stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.88%), Bank of New York Mellon Corp (1.43%), Morgan Stanley (0.59%), Macquarie Group Ltd. (0.55%), Boston Partners (0.54%) and Legal & General Group Plc (0.47%). Company insiders that own Merck & Co., Inc. stock include Adam H Schechter, C Robert Kidder, Julie L Gerberding, Kenneth C Frazier, Michael J Holston, Patricia F Russo, Rita A Karachun, Rochelle B Lazarus, Sanat Chattopadhyay, Thomas H Glocer, Thomas R Cech, Weir Mirian M Graddick and Wendell P Weeks. View Institutional Ownership Trends for Merck & Co., Inc..

MRK stock was sold by a variety of institutional investors in the last quarter, including Federated Investors Inc. PA, Point72 Asset Management L.P., American Century Companies Inc., Natixis, Schroder Investment Management Group, MUFG Securities EMEA plc, Nomura Holdings Inc. and Canada Pension Plan Investment Board. Company insiders that have sold Merck & Co., Inc. company stock in the last year include Adam H Schechter, Julie L Gerberding, Kenneth C Frazier, Michael J Holston, Rita A Karachun, Sanat Chattopadhyay, Thomas H Glocer, Weir Mirian M Graddick and Wendell P Weeks. View Insider Buying and Selling for Merck & Co., Inc..

MRK stock was purchased by a variety of institutional investors in the last quarter, including Senator Investment Group LP, Bank of Montreal Can, Janus Henderson Group PLC, Bank of New York Mellon Corp, Investec Asset Management LTD, Chevy Chase Trust Holdings Inc., Macquarie Group Ltd. and Glenmede Trust Co. NA. View Insider Buying and Selling for Merck & Co., Inc..

Shares of MRK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of MRK stock can currently be purchased for approximately $69.06.

Merck & Co., Inc. has a market capitalization of $178.14 billion and generates $40.12 billion in revenue each year. The company earns $2.39 billion in net income (profit) each year or $3.98 on an earnings per share basis. Merck & Co., Inc. employs 69,000 workers across the globe.

Merck & Co., Inc.'s mailing address is 2000 GALLOPING HILL ROAD, KENILWORTH NJ, 07033. The company can be reached via phone at 908-740-4000 or via email at [email protected]